Intravitreal Gene Therapy Fast Tracked for X-Linked Retinitis Pigmentosa
4D-125 is a gene therapy candidate designed to deliver a functional copy of the RPGR gene to photoreceptors in the retina.
Miscellaneous Ocular Agents
Visomitin Gets Orphan Drug Status for Leber Hereditary Optic Neuropathy
Visomitin is a cardiolipin peroxidation inhibitor designed to sustain and restore mitochondrial function and interrupt apoptosis in mitochondrial conditions.
Growing Evidence Links Pentosan Polysulfate Sodium, Maculopathy
Specific retinal conditions proportionately more common for PPS users versus users of other interstitial cystitis, bladder pain drugs
New Drug Product: Susvimo
This slideshow shows drug information for Susvimo. Click here for the complete Susvimo monograph.
Susvimo Approved for Wet Age-Related Macular Degeneration
Susvimo delivers ranibizumab via ocular implant, which is surgically inserted into the eye during a one-time, outpatient procedure and refilled every 6 months.
First Biosimilar to Lucentis Gets FDA Approval
The approval of Byooviz was based on a review of evidence demonstrating a high degree of similarity to the reference product.
Tebentafusp Gets Priority Review for Metastatic Uveal Melanoma
The application is supported by data from the phase 2 IMCgp100-202 trial that assessed tebentafusp in 378 HLA-A*02:01-positive adults with previously untreated metastatic uveal melanoma.
NSAID Eye Drops May Suffice for Cataract Surgery Prophylaxis
Initiation of prophylactic treatment 3 days before surgery is not superior to initiation on day of surgery
Intravitreal Methotrexate Gets Orphan Drug Status for Retinitis Pigmentosa
The FDA has granted Orphan Drug designation to ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa.
Atropine Plus Patching Ups Visual Acuity in Amblyopic Eye
Visual acuity of the affected eye improved more with atropine plus patching than patching alone in children with severe amblyopia
